Concerns Over Trump’s Drug Pricing Policies

A group of health care leaders expressed concerns on Thursday that President Donald Trump’s most-favored-nation (MFN) drug pricing strategies might hinder future medical innovation, despite acknowledging the president’s broader aim to empower patients regarding their health care expenses.

Charlie Sauer, president of the Market Institute, stated at the Daily Caller Live’s American Healthcare event in Washington, D.C., that “MFN pricing discourages drug companies from making long-term investments.” He mentioned that, as economists, it’s challenging to predict what might not happen in the future.

The discussion, led by Jenn Pellegrino, founder of Defend Forgotten America, also featured insights from Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, and Brent Yessin, CEO of AMC Healthcare, covering topics like drug pricing, rural hospital challenges, and regulatory reform.

Lederman shared that his company recently introduced Tonmya, marking the first new FDA-approved drug for fibromyalgia in 15 years. He pointed out that barriers in managed care could limit patient access to these new treatments.

“It’s disheartening for companies investing in new non-opioid treatments when access remains a hurdle for patients,” he remarked.

He also expressed enthusiasm about FDA Commissioner Marty McCulley’s announcement regarding single-trial approval becoming the standard path for drug approval, indicating it as a significant shift in the process.

“I was amazed by this change today,” Lederman added.

Yessin, a medical attorney with over 30 years of experience, stressed the predicament faced by rural hospitals, with many over 70 years old in need of replacement. He noted the lengthy and costly nature of this process.

“It’s taking far too long and is expensive to replace them,” he commented. “We managed to build a hospital in a factory in about six months, yet the approval could stretch to three years.”

All three panelists agreed on the necessity of reducing bureaucratic barriers, with Yessin candidly critiquing the current regulatory framework.

“Making the situation less problematic would be a refreshing change,” he added.

Lederman underscored the importance of boosting domestic drug manufacturing, highlighting that dependence on foreign suppliers could lead to significant national security challenges.

“It’s alarming that essential medications, like chemotherapy drugs, might not be available due to shortages,” he remarked. “We are overly reliant on manufacturers outside our borders.”